Lavipharm S.A. (ATH:LAVI)

Market Cap	222.67M +66.9%
Revenue (ttm)	55.11M +19.5%
Net Income	3.27M -63.6%
EPS	0.02
Shares Out	168.69M
PE Ratio	108.06
Forward PE	n/a
Dividend	0.02 (1.52%)
Ex-Dividend Date	n/a

Volume	538,265
Average Volume	438,645
Open	1.340
Previous Close	1.302
Day's Range	1.272 - 1.340
52-Week Range	0.650 - 1.406
Beta	0.75
RSI	72.00
Earnings Date	Mar 26, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 282
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2024, Lavipharm's revenue was 52.95 million, an increase of 10.68% compared to the previous year's 47.84 million. Earnings were 8.98 million, an increase of 380.06%.